Agreement in risk prediction between the 21-gene recurrence score assay (Oncotype DX®) and the PAM50 breast cancer intrinsic classifier ™ in early-stage estrogen receptor-positive breast cancer

Oncologist

Volumn 17, Issue 4, 2012, Pages 492-498

  Kelly, Catherine M ^a   Bernard, Philip S ^c   Krishnamurthy, Savitri ^b   Wang, Bailiang ^b   Ebbert, Mark T W ^c   Bastien, Roy R L ^c   Boucher, Kenneth M ^c   Young, Elliana ^b   Iwamoto, Takayuki ^b   Pusztai, Lajos ^b  

^a MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Gene expression profiles; Oncotype DX ); PAM50 assay; Prognosis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; KI 67 ANTIGEN; PROGESTERONE RECEPTOR;

21 GENE RECURRENCE SCORE ASSAY; ADULT; ARTICLE; ASSAY; BREAST CANCER; CANCER PROGNOSIS; CANCER RISK; COMPARATIVE STUDY; FEMALE; GENE EXPRESSION PROFILING; HUMAN; LUMINAL A BREAST CANCER; LUMINAL B BREAST CANCER; MAJOR CLINICAL STUDY; PAM50 BREAST CANCER INTRINSIC CLASSIFIER ASSAY; PREDICTION; PRIORITY JOURNAL;

BREAST NEOPLASMS; COHORT STUDIES; EARLY DETECTION OF CANCER; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; RECEPTORS, ESTROGEN; RISK ASSESSMENT; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84860150463     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0007     Document Type: Article

References (23)

1. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. The N Engl J Med 2009;360: 790-800.
2. Gnant M, Harbeck N, Thomssen C. St. Gallen: Summary of the Consensus Discussion. Breast Care (Basel) 2011;6:136-141.
3. Carlson RW, Brown E, Burstein HJ et al. NCCN Task Force Report: Adjuvant therapy for breast cancer. J Natl Compr Canc Netw 2006;4(suppl 1): S1-S26.
4. Khatcheressian JL, Wolff AC, Smith TJ et al. American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol 2006; 24:5091-5097.
5. Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, nodenegative breast cancer. N Engl J Med 2004;351: 2817-2826.
6. Paik S, Tang G, Shak S et al. Gene expression and benefit of chemotherapy in women with nodenegative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24:3726-3734.
7. Paik S. Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifen. The Oncologist 2007;12:631-635.
8. Mook S, Van't Veer LJ, Rutgers EJ et al. Individualization of therapy using MammaPrint: From development to the MINDACT trial. Cancer Genomics Proteomics 2007;4:147-155.
9. Slodkowska EA, Ross JS. MammaPrint 70-gene signature: Another milestone in personalized medical care for breast cancer patients. Expert Rev Mol Diagn 2009;9:417-422.
10. Wittner BS, Sgroi DC, Ryan PD et al. Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort. Clin Cancer Res 2008;14:2988-2993.
11. Cuadros M, Llanos A. [Validation and clinical application of MammaPrint® in patients with breast cancer]. Med Clin (Barc) 2011;136:627-632. In Spanish.
12. Loi S, Haibe-Kains B, Desmedt C et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 2007;25: 1239-1246.
13. Ma XJ, Salunga R, Dahiya S et al. A fivegene molecular grade index and HOXB13: IL17BR are complementary prognostic factors in early stage breast cancer. Clin Cancer Res 2008; 14:2601-2608.
14. Filho OM, Ignatiadis M, Sotiriou C. Genomic Grade Index: An important tool for assessing breast cancer tumor grade and prognosis. Crit Rev Oncol Hematol 2011;77:20-29.
15. Mathieu MC, KNC, Li H et al. The role of the genomic breast cancer index in predicting pathologic complete response in breast cancer patients treated with neoadjuvant anthracycline plus taxane. J Clin Oncol 2011;29(suppl):573.
16. Bartlett JM, Thomas J, Ross DT et al. Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy. Breast Cancer Res 2010;12:R47.
17. Nielsen TO, Parker JS, Leung S et al. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res 2010;16:5222-5232.
18. Parker JS, Mullins M, Cheang MC et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009;27:1160-1167.
19. Elloumi F, Hu Z, Li Y et al. Systematic bias in genomic classification due to contaminating nonneoplastic tissue in breast tumor samples. BMC Med Genomics 2011;4:54.
20. Iwamoto T, Lee JS, Bianchini G et al. First generation prognostic gene signatures for breast cancer predict both survival and chemotherapy sensitivity and identify overlapping patient populations. Breast Cancer Res Treat 2011;130:155-164.
21. Fan C, Oh DS, Wessels L et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 2006;355:560-569.
22. Kelly CM, Krishnamurthy S, Bianchini G et al. Utility of Oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers. Cancer 2010;116:5161-5167.
23. Cheang MC, Chia SK, Voduc D et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009; 101:736-750.